

## **HCC-UK: ANNUAL REPORT 2017-18**

This annual report covers the period 1 September 2017 to 31 August 2018.

### **Membership**

The BASL Committee has appointed an initial Chair, Dr Aileen Marshall, Consultant Hepatologist, Royal Free Hospital, London. A temporary Committee has also been established, consisting of the Chair, a Secretary, Treasurer/BASL nominee, Conference and Education representative, six members representing medical and scientific fields, and three members without portfolio. Elections will subsequently be held for positions on the HCC-UK Committee.

HCC membership is open to BASL members and other individuals. At the time of writing this report, there were 178 HCC-UK members.

### **Meetings**

The third annual conference of the HCC-UK was held 5-6 April 2018 in London, with the theme *A Focus on Treatment*. This event incorporated research and clinical meetings, covering diverse topics. The aim was to give a broad overview of the latest thinking and advances in the field of Hepatocellular Carcinoma, from its diagnosis, treatments at various stages, through to palliation. The research meeting aimed at fostering collaborative links and new research proposals. Topics ranged from basic science through to early phase clinical trials.

HCC-UK will participate in the International Liver Cancer Association meeting, to be held in London in September 2018.

### **Key achievements**

A collaborative research project has commenced, based on a partnership with Public Health England and the National Cancer Registration and Analysis (NCRAS). The aims of the partnership are to improve the quality of liver cancer data, and to conduct high quality research into clinical outcomes, equity of access to care and the cost-effectiveness of treatments.

Multi-centre research proposals have been submitted to the Cancer Research UK Accelerator programme and Early Detection Research Programme.

HCC-UK has represented BASL in several National Institute of Health and Clinical Excellence technology appraisals of interventional radiology and systemic therapies.

### **Further information**

Please visit the HCC webpages at <https://www.basl.org.uk/index.cfm/content/page/cid/34> and <http://hcc-uk.org/index.html>.